Michelson Diagnostics, the UK-based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces the publication on-line in the British Journal of Dermatology of the full results from an independent clinical study that demonstrates for the first time the clinical value of OCT in the diagnosis of basal cell carcinoma (BCC)1. This observational, prospective, multi-centre study was conducted using the Company’s VivoSight multi-beam OCT device.
This study highlights that using VivoSight OCT is an efficient, non-invasive way to diagnose BCC and has the potential to reduce avoidable biopsies and surgery, thereby reducing scarring for patients.
To view the full press release please click here
To view the paper abstract and download the full paper for free from the British Journal of Dermatology, click here